News
Media Coverage

Thursday, November 20, 2014

Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s

buy viagra low cost thesis dedication template propecia frontal hair why doesn't viagra work for me essay collections by writer thesis paper examples pdf english essay writing practice click https://ahamediagroup.com/blog/essay-assignment-help/49/ https://www.iama.edu/clinics/online-viagra-in-canada.html thesis statement of the problem sample buy viagra cheap online fast shipping kaboom viagra math homework help fractions source url go to link source site mex select viagra products follow url viagra retail cost dissertation writing coach pharmacie en ligne fiable pour viagra thesis statement examples the crucible side effects for doxycycline https://nrha.org/research/broadway-services-viagra-reviews/51/ http://owjn.org/12389-help-with-my-social-studies-homework/ AlzforumStem cells have been hailed, and hailed some more, as a breakthrough technology. All the same, they have been slow to make real inroads in the understanding and treatment of Alzheimer’s disease. That is about to change, according to scientists who spoke at “Accelerating the Cure for Alzheimer’s Disease through Regenerative Medicine.” READ MORE HERE

Wednesday, August 20, 2014

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Alzheimer's News TodayAn intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies developing stem cell therapies for Alzheimer’s disease and dementia. READ MORE HERE

Stemedica Posts Alzheimer’s Stem Cell Data

BioPortfolio LogoStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE

Stemedica International Posts Alzheimer’s Stem Cell Data

DD&D MagStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE